Novo Nordisk is trading at $46.49, up 3.04% following the September 1, 2026 launch of the Wegovy pill in Germany.
- Germany is the first EU market for the oral treatment.
- Investors are assessing demand amid intensifying competition from Eli Lilly.
- Healthcare-sector strength, with XLV up 1.26%, is adding support.